Rein Therapeutics, Inc. RNTX
Rein Therapeutics, Inc. (Nasdaq: RNTX) is a respiratory drug developer. Its lead program, LTI-03 (inhaled Cav1-derived peptide), is in Phase 2 for Idiopathic pulmonary fibrosis (IPF). Its next catalyst on record is LTI-03: Company may report data from Phase 2 trial of LTI-03 in the second half of 2026. (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: LTI-03 — Company may report data from Phase 2 trial of LTI-03 in the second half of 2026. (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LTI-03 (RENEW Ph2) | Idiopathic pulmonary fibrosis | protein/peptide | Phase 2 |
| LTI-01 (proenzyme; development paused indefinitely) | Loculated pleural effusion | protein/peptide | Phase 2 |
| Cystic fibrosis program (paused) | Cystic fibrosis | unclear | Pre-clinical |
| Cav1 peptide program for systemic fibrosis (paused) | Systemic fibrosis | protein/peptide | Pre-clinical |
Recent results and decisions
- Sep 4, 2026met LTI-03 Phase 1b clinical trial met primary endpoint with high dose (10mg) and low dose (5mg) well-tolerated and no treatment-related serious adverse events.
Phase 1b clinical trial met primary endpoint: High dose LTI-03 (10mg) and low dose LTI-03 (5mg) was well-tolerated; no treatment-related SAEs.
Filing - Sep 4, 2026started Rein Therapeutics is now enrolling the RENEW Phase 2 clinical trial for LTI-03 in IPF (NCT06968845).
NOW ENROLLING LTI-03 Idiopathic Pulmonary Fibrosis
Filing - Nov 3, 2025hold lifted FDA lifted the full clinical hold on the Phase 2 RENEW trial of LTI-03 in IPF; U.S. enrollment to resume late 2025 or early 2026.
The FDA's decision follows a review of Rein's submission, which addressed all of the agency's concerns.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.